Research brief · 2026-09-09
What Does Tesamorelin Actually Do? What the Research Shows
Tesamorelin is a synthetic, stabilized analog of growth hormone releasing hormone, the hypothalamic signal that tells the pituitary to release growth hormone. Unlike growth hormone injections, it works upstream: it prompts the body's own pituitary to release more growth hormone, which in turn raises IGF-1. It is a prescription medication, approved by the FDA in November 2010 as Egrifta.
The approval is narrow. Tesamorelin is approved for a single use: reducing excess visceral abdominal fat in HIV-infected adults with lipodystrophy, a fat-redistribution syndrome linked to antiretroviral therapy. It is not approved for weight loss in the general population, for age-related growth hormone decline, or for athletic or anti-aging use.
The registration trial by Falutz and colleagues, published in the New England Journal of Medicine in 2007, randomized 412 HIV-infected adults with excess abdominal fat to daily tesamorelin or placebo for 26 weeks. Visceral fat measured by CT scan fell 15.2% on tesamorelin and rose 5.0% on placebo. Triglycerides and the cholesterol ratio improved, and IGF-1 rose 81% on the drug, confirming it was doing what it was designed to do.
A pooled analysis of two Phase 3 trials with a 26-week extension, published in the Journal of Clinical Endocrinology and Metabolism in 2010, followed 806 participants. The visceral fat reduction was sustained through 52 weeks in people who stayed on the drug, roughly 17 to 18% below baseline, with no clinically meaningful change in glucose. Participants switched to placebo saw the fat return, so the effect does not persist without continued treatment.
The limits are clear. Every pivotal trial enrolled HIV-infected adults with a distinct kind of fat accumulation; nothing here applies to ordinary visceral fat in people without HIV. Data beyond about a year is thin, and there is essentially no trial evidence for muscle, athletic or anti-aging use. Tesamorelin is also prohibited at all times by the World Anti-Doping Agency. Decisions about this medication belong with a physician.
Sources
- Falutz J et al., Metabolic effects of a growth hormone-releasing factor in patients with HIV (registration trial, n=412)
- New England Journal of Medicine 2007
- Falutz J et al., pooled analysis of two Phase 3 trials with 26-week extension (n=806)
- Journal of Clinical Endocrinology & Metabolism 2010
- ClinicalTrials.gov NCT00123253, TH9507 in patients with HIV-associated lipodystrophy
- ClinicalTrials.gov 2007
Peptide Proof reports what studies found. We do not give medical advice, dosing guidance, or treatment recommendations.